MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

0.9080
-0.0120
-1.30%
Closed 16:00 08/07 EDT
OPEN
0.9700
PREV CLOSE
0.9200
HIGH
0.9725
LOW
0.8647
VOLUME
789.79K
TURNOVER
--
52 WEEK HIGH
1.670
52 WEEK LOW
0.5339
MARKET CAP
136.04M
P/E (TTM)
-2.2872
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LCTX stock price target is 4.250 with a high estimate of 6.00 and a low estimate of 3.000.

EPS

LCTX News

More
Lineage Cell Therapeutics EPS in-line, misses on revenue
Lineage Cell Therapeutics (NYSEMKT:LCTX): Q2 GAAP EPS of -$0.04 in-line. Revenue of $0.39M (-50.0% Y/Y) misses by $0.25M. Press Release
seekingalpha · 22h ago
Lineage Cell Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on All Clinical Programs
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today reported financial and operating results for the second quarter ended June 30, 2020. Lineage m
Business Wire · 1d ago
Lineage Cell Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its second quarter 2020 financial and operating results on Thurs
Business Wire · 07/30 12:00
Israel Innovation Authority extends development grant for Lineage Cell OpRegen
The Israel Innovation Authority (IIA) has extended its development grant in support of Lineage Cell Therapeutics' (NYSEMKT:LCTX) OpRegen, the retinal pigme
seekingalpha · 07/06 18:10
Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority
Business Wire · 07/06 13:00
Lineage Cell Therapeutics Announces Extension Of OpRegen Development Grant From Israel Innovation Authority
Benzinga · 07/06 12:10
Lineage Cell Therapeutics Is A High-Risk But High-Reward Opportunity To Consider
Seeking Alpha - Article · 07/03 02:15
Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury
Business Wire · 06/25 13:00

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Symbol
Price
%Change

About LCTX

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
More

Webull offers kinds of Lineage Cell Therapeutics Inc stock information, including AMEX:LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.